Background: Recent guidelines suggest that, for venous thromboembolism (VTE), standard
doses of apixaban are appropriate in patients with body mass index (BMI)> 40 kg/m2 or> …

Background Direct oral anticoagulants such as dabigatran are the preferred anticoagulant in
treating atrial fibrillation (AF) patients due to their effectiveness and safety. Whether this …

Atrial fibrillation (AF) patients are often high risk being elderly and having multiple
comorbidities. Many risk factors are established to be associated with new onset incident AF …

Phase III clinical trials for individual direct oral anticoagulants (DOACs) contained a limited
representation of subjects with abnormal body weight, which were mostly limited to a BMI> …

Background and aim Atrial fibrillation (AF) is the most frequently observed cardiac
arrhythmia in clinical settings. Obesity can influence the efficacy of the treatment …

Methods We carried out a comprehensive search of electronic databases from inception to
June 2023 for eligible studies reporting on the efficacy and safety of direct oral …

Background Recent guidelines recommend using direct oral anticoagulants (DOACs) as first-
line agents in patients with non-valvular atrial fibrillation (NVAF). Research is currently …

Abstract Aim The “2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management
of Patients With Atrial Fibrillation” provides recommendations to guide clinicians in the …

Objective Through predictable pharmacokinetics—including a convenient fixed-dose
regimen, direct oral anticoagulants (DOACs) are preferred over previous treatments in …

Background: Apixaban has been increasingly utilized for various FDA-approved indications,
including stroke prevention and venous thromboembolism (VTE) treatment in patients with …